#Article : Newly Identified Transcriptomic #Biomarkers and #Gene Signature of Pathological Complete Response to Induction #Chemoimmunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma (#HNSCC) doi.org/10.1002/mco2...
studied by Prof. Udo S. Gaipl and his group

#Letter in #MedComm
Remarkable Responses to Chemoimmunotherapy in Ultra-Rare Urachal Cancer: A Case Series and Reverse Translational Research doi.org/10.1002/mco2... , studied by Dr. Hiroshi Kotani

#URCA #ICB #GastricCancer #CRC #chemoimmunotherapy

Outstanding oral presentation at #EANO2025 in Prague, now published in #NeuroOncology: the Multicenter Randomized Phase II Study of R-MPV-A #Chemoimmunotherapy With or Without Low-Dose Whole-Brain #Radiotherapy for Newly-Diagnosed Primary... by Antonio Omuro & colleagues.
👉 doi.org/10.1093/neuo...

Evolution Trial Evaluates Radiotherapy-Free Chemoimmunotherapy with Pembrolizumab in Locally Advanced NSCLC with High PD-L1 Expression

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Evolution #Chemoimmunotherapy #Pembrolizumab #NSCLC

Individualized Therapy Associated With Greater Rates of Undetectable MRD, Extended PFS in CLL | ASH Clinical News | American Society of Hematology

In patients with treatment-naïve #CLL, MRD-guided therapy with #ibrutinib plus #venetoclax led to greater rates of undetectable MRD, extended PFS, and increased OS than ibrutinib alone or #chemoimmunotherapy, especially among patients with unmutated IGHV: ow.ly/oA2u50WWZZc #HemeSky #HemeOnc

New Paper Alert: Real-World Study Confirms Chemoimmunotherapy Improves Survival in Resectable NSCLC, But Usage Remains Low - OncoDaily Chemoimmunotherapy improves metastasis-free survival in stage II–IIIA NSCLC, yet under 30% of patients receive it. Real-world US analysis.

New Paper Alert: Real-World Study Confirms Chemoimmunotherapy Improves Survival in Resectable NSCLC, But Usage Remains Low

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Chemoimmunotherapy #NSCLC

Innovative Partnership Behind Chemoimmunotherapy Drug Development Announced by Sanyou Biopharmaceuticals and Medicovestor Sanyou Biopharmaceuticals and Medicovestor have joined forces to develop advanced chemoimmunotherapy treatments using cutting-edge antibody-drug conjugates.

Innovative Partnership Behind Chemoimmunotherapy Drug Development Announced by Sanyou Biopharmaceuticals and Medicovestor #United_States #New_York #Sanyou_Bio #Medicovestor #Chemoimmunotherapy